Company Overview

Stryker Corporation is a global leader in medical technologies, committed to making healthcare better alongside its customers. The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics designed to improve patient and healthcare outcomes. Founded in 1941, Stryker is headquartered in Portage, Michigan, and impacts over 150 million patients annually worldwide. Its products are sold through company-owned subsidiaries, branches, and third-party dealers/distributors in approximately 75 countries.

Business Segments

Stryker operates through two primary business segments:

MedSurg and Neurotechnology Segment

This segment contributed 59.7% of total revenue in 2024, with net sales reaching $13.5 billion, an 11.1% year-over-year increase. Key product areas within this segment include:

- Medical Equipment: $3.85 billion in sales, up 11.4%.

- Endoscopy: $3.39 billion in sales, a 10.5% gain.

- Surgical Instruments: $2.83 billion in sales, reflecting an 11.9% increase.

- Neurotechnology Products: Includes neurovascular devices and neurosurgical instruments.

Orthopaedics Segment

This segment contributed 40.3% of total revenue in 2024, with net sales of $9.1 billion, an 8.9% increase year-over-year. Products within this segment include:

- Implants: For total joint replacements (hip, knee, shoulder), trauma, and extremities surgeries.

- Orthopedics Products: Primarily implants for hip and knee joint replacements, as well as trauma and extremities surgeries.

- Sports Medicine and Foot and Ankle Implants.

Financial Performance

2024 Financial Highlights

- Consolidated Net Sales: Increased 10.2% year-over-year to $22.6 billion for the full year 2024 (10.7% in constant currency). Quarterly net sales increased 10.7%.

- Organic Growth: Exceeded 10% for both Q4 and the full year 2024.

- Adjusted EPS Growth: Achieved a 16% growth in Q4 and 15% for the full year 2024 compared to 2023.

- Cash Position: $4.5 billion in Cash and Marketable Securities at year-end 2024.

- Cash from Operations: $4.2 billion for the full year 2024.

Market Capitalization

As of August 2025, Stryker Corporation has a market capitalization of $149.43 Billion USD. This positions Stryker as the 116th most valuable company globally.

Strategic Initiatives and Growth Drivers

Innovation and R&D Investment

Stryker's commitment to innovation is evident through its substantial R&D investment. For the nine months of 2024, R&D expenses amounted to $1,108 million, representing 6.9% of net sales. This investment fuels the development of advanced products across its segments, ensuring a competitive edge in the healthcare market.

Mergers and Acquisitions

Stryker strategically enhanced its portfolio through several acquisitions in 2024:

- Inari Medical Acquisition: Expanded presence in the fast-growing peripheral vascular market.

- SERF SAS Acquisition (March 2024): Completed acquisition of the France-based joint replacement company.

- Care.ai Acquisition (September 2024): Acquisition of an AI healthcare firm.

These acquisitions contributed significantly to the company's strong financial performance.

Robotics Leadership

Stryker has established a leading position in robotic-assisted surgery with its Mako systems, benefiting from a significant head start over competitors like Zimmer Biomet and Johnson & Johnson. Strong demand for Mako robotic-assisted surgery systems continues, with record installations in the US.

Competitive Position

Stryker is a top-tier competitor across attractive medical markets, including orthopedic implants, surgical instruments, endoscopy, and neurovascular devices. The company boasts a long history of innovation, maintaining:

- 35% worldwide reconstructive market share.

- 50% worldwide MedSurg market share.

- 15% worldwide Neurotechnology and Spine market share.

This sustained innovation and market leadership allow Stryker to earn attractive economic profits.

2025 Outlook

Based on strong momentum exiting 2024, sustained procedural volumes, robust capital product demand, and presence in healthy end markets, Stryker provides the following guidance for 2025:

- Organic Net Sales Growth: Expected to be in the range of 8.0% to 9.0%.

- Adjusted Net Earnings Per Diluted Share: Expected to be in the range of $13.45 to $13.70.

- Capital Spending: Guidance is $800 million to $850 million.

Stryker continues to demonstrate strong operational performance and strategic growth across its diversified medical technology portfolio, solidifying its leadership in the evolving healthcare landscape.